Cargando…
Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension
There are limited published data defining survival and treatment response in patients with mild lung disease and/or reduced gas transfer who fulfil diagnostic criteria for idiopathic pulmonary arterial hypertension (IPAH). Patients diagnosed with IPAH between 2001 and 2019 were identified in the ASP...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270350/ https://www.ncbi.nlm.nih.gov/pubmed/32108045 http://dx.doi.org/10.1183/13993003.00041-2020 |
_version_ | 1783541889123745792 |
---|---|
author | Lewis, Robert A. Thompson, A.A. Roger Billings, Catherine G. Charalampopoulos, Athanasios Elliot, Charlie A. Hamilton, Neil Hill, Catherine Hurdman, Judith Rajaram, Smitha Sabroe, Ian Swift, Andy J. Kiely, David G. Condliffe, Robin |
author_facet | Lewis, Robert A. Thompson, A.A. Roger Billings, Catherine G. Charalampopoulos, Athanasios Elliot, Charlie A. Hamilton, Neil Hill, Catherine Hurdman, Judith Rajaram, Smitha Sabroe, Ian Swift, Andy J. Kiely, David G. Condliffe, Robin |
author_sort | Lewis, Robert A. |
collection | PubMed |
description | There are limited published data defining survival and treatment response in patients with mild lung disease and/or reduced gas transfer who fulfil diagnostic criteria for idiopathic pulmonary arterial hypertension (IPAH). Patients diagnosed with IPAH between 2001 and 2019 were identified in the ASPIRE (Assessing the Spectrum of Pulmonary Hypertension Identified at a Referral Centre) registry. Using prespecified criteria based on computed tomography (CT) imaging and spirometry, patients with a diagnosis of IPAH and no lung disease were termed IPAH(no-LD) (n=303), and those with minor/mild emphysema or fibrosis were described as IPAH(mild-LD) (n=190). Survival was significantly better in IPAH(no-LD) than in IPAH(mild-LD) (1- and 5-year survival 95% and 70% versus 78% and 22%, respectively; p<0.0001). In the combined group of IPAH(no-LD) and IPAH(mild-LD), independent predictors of higher mortality were increasing age, lower diffusing capacity of the lung for carbon monoxide (D(LCO)), lower exercise capacity and a diagnosis of IPAH(mild-LD) (all p<0.05). Exercise capacity and quality of life improved (both p<0.0001) following treatment in patients with IPAH(no-LD), but not IPAH(mild-LD). A proportion of patients with IPAH(no-LD) had a D(LCO) <45%; these patients had poorer survival than patients with D(LCO) ≥45%, although they demonstrated improved exercise capacity following treatment. The presence of even mild parenchymal lung disease in patients who would be classified as IPAH according to current recommendations has a significant adverse effect on outcomes. This phenotype can be identified using lung function testing and clinical CT reports. Patients with IPAH, no lung disease and severely reduced D(LCO) may represent a further distinct phenotype. These data suggest that randomised controlled trials of targeted therapies in patients with these phenotypes are required. |
format | Online Article Text |
id | pubmed-7270350 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-72703502020-06-09 Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension Lewis, Robert A. Thompson, A.A. Roger Billings, Catherine G. Charalampopoulos, Athanasios Elliot, Charlie A. Hamilton, Neil Hill, Catherine Hurdman, Judith Rajaram, Smitha Sabroe, Ian Swift, Andy J. Kiely, David G. Condliffe, Robin Eur Respir J Original Articles There are limited published data defining survival and treatment response in patients with mild lung disease and/or reduced gas transfer who fulfil diagnostic criteria for idiopathic pulmonary arterial hypertension (IPAH). Patients diagnosed with IPAH between 2001 and 2019 were identified in the ASPIRE (Assessing the Spectrum of Pulmonary Hypertension Identified at a Referral Centre) registry. Using prespecified criteria based on computed tomography (CT) imaging and spirometry, patients with a diagnosis of IPAH and no lung disease were termed IPAH(no-LD) (n=303), and those with minor/mild emphysema or fibrosis were described as IPAH(mild-LD) (n=190). Survival was significantly better in IPAH(no-LD) than in IPAH(mild-LD) (1- and 5-year survival 95% and 70% versus 78% and 22%, respectively; p<0.0001). In the combined group of IPAH(no-LD) and IPAH(mild-LD), independent predictors of higher mortality were increasing age, lower diffusing capacity of the lung for carbon monoxide (D(LCO)), lower exercise capacity and a diagnosis of IPAH(mild-LD) (all p<0.05). Exercise capacity and quality of life improved (both p<0.0001) following treatment in patients with IPAH(no-LD), but not IPAH(mild-LD). A proportion of patients with IPAH(no-LD) had a D(LCO) <45%; these patients had poorer survival than patients with D(LCO) ≥45%, although they demonstrated improved exercise capacity following treatment. The presence of even mild parenchymal lung disease in patients who would be classified as IPAH according to current recommendations has a significant adverse effect on outcomes. This phenotype can be identified using lung function testing and clinical CT reports. Patients with IPAH, no lung disease and severely reduced D(LCO) may represent a further distinct phenotype. These data suggest that randomised controlled trials of targeted therapies in patients with these phenotypes are required. European Respiratory Society 2020-06-04 /pmc/articles/PMC7270350/ /pubmed/32108045 http://dx.doi.org/10.1183/13993003.00041-2020 Text en Copyright ©ERS 2020 http://creativecommons.org/licenses/by/4.0/This version is distributed under the terms of the Creative Commons Attribution Licence 4.0. |
spellingShingle | Original Articles Lewis, Robert A. Thompson, A.A. Roger Billings, Catherine G. Charalampopoulos, Athanasios Elliot, Charlie A. Hamilton, Neil Hill, Catherine Hurdman, Judith Rajaram, Smitha Sabroe, Ian Swift, Andy J. Kiely, David G. Condliffe, Robin Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension |
title | Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension |
title_full | Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension |
title_fullStr | Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension |
title_full_unstemmed | Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension |
title_short | Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension |
title_sort | mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270350/ https://www.ncbi.nlm.nih.gov/pubmed/32108045 http://dx.doi.org/10.1183/13993003.00041-2020 |
work_keys_str_mv | AT lewisroberta mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension AT thompsonaaroger mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension AT billingscatherineg mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension AT charalampopoulosathanasios mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension AT elliotcharliea mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension AT hamiltonneil mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension AT hillcatherine mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension AT hurdmanjudith mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension AT rajaramsmitha mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension AT sabroeian mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension AT swiftandyj mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension AT kielydavidg mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension AT condlifferobin mildparenchymallungdiseaseandorlowdiffusioncapacityimpactssurvivalandtreatmentresponseinpatientsdiagnosedwithidiopathicpulmonaryarterialhypertension |